Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

The Short-term Effects of a Cyberbullying Prevention Intervention for Parents of Middle School Students.

Roberto AJ, Eden J, Deiss DM, Savage MW, Ramos-Salazar L.

Int J Environ Res Public Health. 2017 Sep 9;14(9). pii: E1038. doi: 10.3390/ijerph14091038.

2.

Theory-Based Formative Research on an Anti-Cyberbullying Victimization Intervention Message.

Savage MW, Deiss DM Jr, Roberto AJ, Aboujaoude E.

J Health Commun. 2017 Feb;22(2):124-134. doi: 10.1080/10810730.2016.1252818. Epub 2017 Jan 19.

PMID:
28103179
3.

Insulin Infusion Set Use: European Perspectives and Recommendations.

Deiss D, Adolfsson P, Alkemade-van Zomeren M, Bolli GB, Charpentier G, Cobelli C, Danne T, Girelli A, Mueller H, Verderese CA, Renard E.

Diabetes Technol Ther. 2016 Sep;18(9):517-24. doi: 10.1089/dia.2016.07281.sf. Epub 2016 Aug 15.

4.
5.

Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial.

Knip M, Åkerblom HK, Becker D, Dosch HM, Dupre J, Fraser W, Howard N, Ilonen J, Krischer JP, Kordonouri O, Lawson ML, Palmer JP, Savilahti E, Vaarala O, Virtanen SM; TRIGR Study Group.

JAMA. 2014 Jun 11;311(22):2279-87. doi: 10.1001/jama.2014.5610.

6.

Outcome evaluation results of school-based cybersafety promotion and cyberbullying prevention intervention for middle school students.

Roberto AJ, Eden J, Savage MW, Ramos-Salazar L, Deiss DM.

Health Commun. 2014;29(10):1029-42. doi: 10.1080/10410236.2013.831684. Epub 2014 Jan 21.

PMID:
24446820
7.

Growth differences between North American and European children at risk for type 1 diabetes.

Nucci AM, Becker DJ, Virtanen SM, Cuthbertson D, Softness B, Huot C, Wasikowa R, Dosch HM, Akerblom HK, Knip M; TRIGR Study Group.

Pediatr Diabetes. 2012 Aug;13(5):425-31. doi: 10.1111/j.1399-5448.2011.00840.x. Epub 2012 Jan 17.

8.

[Successful treatment with liraglutide in type 1 diabetes and MODY].

Deiss D, Diederich S, Kordonouri O.

Dtsch Med Wochenschr. 2011 May;136(21):1116-20. doi: 10.1055/s-0031-1280520. Epub 2011 May 17. German.

PMID:
21590630
9.

Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis.

Garin I, Edghill EL, Akerman I, Rubio-Cabezas O, Rica I, Locke JM, Maestro MA, Alshaikh A, Bundak R, del Castillo G, Deeb A, Deiss D, Fernandez JM, Godbole K, Hussain K, O'Connell M, Klupa T, Kolouskova S, Mohsin F, Perlman K, Sumnik Z, Rial JM, Ugarte E, Vasanthi T; Neonatal Diabetes International Group, Johnstone K, Flanagan SE, Martínez R, Castaño C, Patch AM, Fernández-Rebollo E, Raile K, Morgan N, Harries LW, Castaño L, Ellard S, Ferrer J, Perez de Nanclares G, Hattersley AT.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3105-10. doi: 10.1073/pnas.0910533107. Epub 2010 Jan 28.

10.

Intensive Care Unit Insulin Delivery Algorithms: Why So Many? How to Choose?

Steil GM, Deiss D, Shih J, Buckingham B, Weinzimer S, Agus MS.

J Diabetes Sci Technol. 2009 Jan;3(1):125-140.

11.

Expanded clinical spectrum in hepatocyte nuclear factor 1b-maturity-onset diabetes of the young.

Raile K, Klopocki E, Holder M, Wessel T, Galler A, Deiss D, Müller D, Riebel T, Horn D, Maringa M, Weber J, Ullmann R, Grüters A.

J Clin Endocrinol Metab. 2009 Jul;94(7):2658-64. doi: 10.1210/jc.2008-2189. Epub 2009 May 5.

PMID:
19417042
12.

HNF1B abnormality (mature-onset diabetes of the young 5) in children and adolescents: high prevalence in autoantibody-negative type 1 diabetes with kidney defects.

Raile K, Klopocki E, Wessel T, Deiss D, Horn D, Müller D, Ullmann R, Grüters A.

Diabetes Care. 2008 Nov;31(11):e83. doi: 10.2337/dc08-0920. No abstract available.

PMID:
18955710
13.

Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes.

Rubio-Cabezas O, Minton JA, Caswell R, Shield JP, Deiss D, Sumnik Z, Cayssials A, Herr M, Loew A, Lewis V, Ellard S, Hattersley AT.

Diabetes Care. 2009 Jan;32(1):111-6. doi: 10.2337/dc08-1188. Epub 2008 Oct 17.

14.
15.

Glucose control in pediatric intensive care unit patients using an insulin-glucose algorithm.

Wintergerst KA, Deiss D, Buckingham B, Cantwell M, Kache S, Agarwal S, Wilson DM, Steil G.

Diabetes Technol Ther. 2007 Jun;9(3):211-22.

PMID:
17561791
16.

Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes.

Deiss D, Kordonouri O, Hartmann R, Hopfenmüller W, Lüpke K, Danne T.

Pediatr Diabetes. 2007 Jun;8(3):157-62.

PMID:
17550426
17.

Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring.

Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M.

Diabetes Care. 2006 Dec;29(12):2730-2. No abstract available.

PMID:
17130215
19.

Age-specific advantages of continuous subcutaneous insulin infusion as compared with multiple daily injections in pediatric patients: one-year follow-up comparison by matched-pair analysis.

Kordonouri O, Hartmann R, Lauterborn R, Barnekow C, Hoeffe J, Deiss D.

Diabetes Care. 2006 Jan;29(1):133-4. No abstract available.

PMID:
16373909
20.

Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty.

Kordonouri O, Hartmann R, Deiss D, Wilms M, Grüters-Kieslich A.

Arch Dis Child. 2005 Apr;90(4):411-4.

Supplemental Content

Loading ...
Support Center